Country: United States
Language: English
Source: NLM (National Library of Medicine)
GLIPIZIDE (UNII: X7WDT95N5C) (GLIPIZIDE - UNII:X7WDT95N5C)
Apotheca Inc.
ORAL
PRESCRIPTION DRUG
Glipizide Tablets, USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Glipizide Tablets, USP are contraindicated in patients with: - Known hypersensitivity to the drug. - Type 1 diabetes mellitus, diabetic ketoacidosis, with or without coma. This condition should be treated with insulin.
The 10 mg tablet is white, round biconvex tablets with bisect, debossed '10' on one side. NDC 12634-790-00 Bottles of 10 NDC 12634-790-01 Bottles of 100 NDC 12634-790-09 Bottles of 35 NDC 12634-790-12 Bottles of 120 NDC 12634-790-18 Bottles of 180 NDC 12634-790-40 Bottles of 40 NDC 12634-790-42 Bottles of 42 NDC 12634-790-45 Bottles of 45 NDC 12634-790-50 Bottles of 50 NDC 12634-790-52 Blister Pack of 12 NDC 12634-790-54 Blister Pack of 14 NDC 12634-790-57 Blister Pack of 20 NDC 12634-790-59 Blister Pack of 30 NDC 12634-790-60 Bottles of 60 NDC 12634-790-61 Blister Pack of 10 NDC 12634-790-63 Blister Pack of 3 NDC 12634-790-66 Blister Pack of 6 NDC 12634-790-67 Blister Pack of 7 NDC 12634-790-69 Blister Pack of 9 NDC 12634-790-71 Bottles of 30 NDC 12634-790-74 Bottles of 24 NDC 12634-790-78 Bottles of 28 NDC 12634-790-79 Bottles of 25 NDC 12634-790-80 Bottles of 20 NDC 12634-790-81 Bottles of 21 NDC 12634-790-82 Bottles of 12 NDC 12634-790-84 Bottles of 14 NDC 12634-790-85 Bottles of 15 NDC 12634-790-90 Bottles of 90 NDC 12634-790-91 Blister Pack of 1 NDC 12634-790-92 Bottles of 2 NDC 12634-790-93 Bottles of 3 NDC 12634-790-94 Bottles of 4 NDC 12634-790-95 Bottles of 5 NDC 12634-790-96 Bottles of 6 NDC 12634-790-97 Bottles of 7 NDC 12634-790-98 Bottles of 8 NDC 12634-790-99 Bottles of 9 Store at 20º to 25 ºC (68º to 77º F) [see USP Controlled Room Temperature].
Abbreviated New Drug Application
GLIPIZIDE- GLIPIZIDE TABLET APOTHECA INC. ---------- GLIPIZIDE TABLETS, USP _FOR ORAL USE_ DESCRIPTION Glipizide is an oral blood-glucose-lowering drug of the sulfonylurea class. The Chemical Abstracts name of glipizide is 1-cyclohexyl-3-[[p-[2-(5-methylpyrazine- carboxamido)ethyl]phenyl]sulfonyl]urea. The molecular formula is C H N O S; the molecular weight is 445.55; the structural formula is shown below: Glipizide is a whitish, odorless powder with a pKa of 5.9. It is insoluble in water and alcohols, but soluble in 0.1 _N_ NaOH; it is freely soluble in dimethylformamide. Each tablet, for oral administration, contains 5 mg or 10 mg glipizide. In addition, each tablet contains the following inactive ingredients: anhydrous lactose, microcrystalline cellulose, corn starch, silicon dioxide, stearic acid. Glipizide Tablets, USP 5 mg and 10 mg meet USP Dissolution Test 2. CLINICAL PHARMACOLOGY MECHANISM OF ACTION The primary mode of action of glipizide in experimental animals appears to be the stimulation of insulin secretion from the beta cells of pancreatic islet tissue and is thus dependent on functioning beta cells in the pancreatic islets. In humans, glipizide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which glipizide lowers blood glucose during long-term administration has not been clearly established. In man, stimulation of insulin secretion by glipizide in response to a meal is undoubtedly of major importance. Fasting insulin levels are not elevated even on long-term glipizide administration, but the postprandial insulin response continues to be enhanced after at least 6 months of treatment. The insulinotropic response to a meal occurs within 30 minutes after an oral dose of glipizide in diabetic patients, but elevated insulin levels do not persist beyond the time of the meal challenge. 21 27 5 4 Extrapancreatic effects may play a part in the mechanism of action o Read the complete document